Sector News

Perrigo spurns second offer from Mylan

April 27, 2015
Life sciences
The Perrigo-Mylan-Teva takeover saga has taken another turn after Perrigo again spurned Mylan’s advances, rejecting a second bid from the generics giant.
 
Desperate to protect itself from a Teva takover, Mylan has laid a new bid on the table for Perrigo of $60 cash and 2.2 of its share’s for every remaining share in the Dublin, Ireland-based firm. This, it claims, values the deal at around $222 per Perrigo share.
 
However, Perrigo has taken a different stance on Mylan’s new proposal, arguing that, based in its own calculations, which uses Mylan’s lower share price before rumours of Teva’s interest started to grow, the offer actually only equates to $188 a share.
 
This, it notes, falls under the $205 a share proposed by Mylan early last week. As such, Perrigo’s Board “strongly advised” the firm’s shareholders “to take no action in relation to the offer”.
 
Mylan is yet to respond to Teva’s $40-billion takeover bid, but indications are that it seems reluctant to accept.
 
By Selina McKee
 
Source: Pharma Times

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach